A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors Clinical Trial

Official title:

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06349811
• Other study ID #: BL-M05D1-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: May 2024
• Est. completion date: May 2026

Study information

• Verified date: April 2024
• Source: Sichuan Baili Pharmaceutical Co., Ltd.
• Contact: Sa Xiao, PHD
• Phone: +8615013238943
• Email: xiaosa[@]baili-pharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: May 2026
• Est. primary completion date: May 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Sign the informed consent form voluntarily and follow the protocol requirements;

2. Gender is not limited;

3. Age: =18 years old and =75 years old;

4. Expected survival time =3 months;

5. locally advanced or metastatic solid tumors confirmed by histopathology and/or cytology with failure or intolerance to standard treatment or no standard treatment at present;

6. Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 3 years;

7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

8. ECOG 0 or 1;

9. The toxicity of previous antineoplastic therapy has returned to = grade 1 as defined by NCI-CTCAE v5.0;

10. No severe cardiac dysfunction, left ventricular ejection fraction =50%;

11. No blood transfusion, no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;

12. Coagulation function: international normalized ratio (INR) =1.5, and activated partial thromboplastin time (APTT) =1.5ULN;

13. Urinary protein =2+ or =1000mg/24h;

14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria:

1. Chemotherapy, biological therapy, immunotherapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral fluorouracil or palliative radiotherapy within 2 weeks before the first dose; Chinese patent medicine within 2 weeks before the first administration;

2. History of severe cardiovascular and cerebrovascular diseases;

3. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

4. active autoimmune and inflammatory diseases;

5. other malignant tumors diagnosed within 5 years before the first dose;

6. Hypertension poorly controlled by two antihypertensive drugs;

7. had a history of ILD or a suspicion of such disease on imaging during screening; The patient was diagnosed with grade =1 radiation pneumonitis according to the RTOG/EORTC definition;

8. Pulmonary disease defined as grade =2 according to CTCAE v5.0; Pulmonary diseases lead to clinically severe respiratory function impairment;

9. patients with poor glycemic control;

10. patients with active central nervous system metastases;

11. Patients with massive or symptomatic effusions, or poorly controlled effusions;

12. Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large blood vessels;

13. had a history of pulmonary embolism or a thrombotic event requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;

14. had a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or any of BL-M05D1 ingredients;

15. prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

16. The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;

17. human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;

18. active infection requiring systemic therapy;

19. had participated in another clinical trial within 4 weeks before the first dose;

20. pregnant or lactating women;

21. The investigator did not consider it appropriate to apply other criteria for participation in the trial.

Related Conditions & MeSH terms

• Locally Advanced or Metastatic Solid Tumors
• Neoplasms

Intervention

Drug:
• BL-M05D1
Administration by intravenous infusion for a cycle of 3 weeks.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Sichuan Baili Pharmaceutical Co., Ltd.	Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase Ia: Dose limiting toxicity (DLT)	DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.	Up to 21 days after the first dose
Primary	Phase Ia: Maximum tolerated dose (MTD)	MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle .	Up to 21 days after the first dose
Primary	Phase Ib: Recommended Phase II Dose (RP2D)	The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M05D1.	Up to approximately 24 months
Secondary	Treatment-Emergent Adverse Event (TEAE)	TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M05D1 . The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M05D1.	Up to approximately 24 months
Secondary	Cmax	Maximum serum concentration (Cmax) of BL-M05D1 will be investigated.	Up to approximately 24 months
Secondary	Tmax	Time to maximum serum concentration (Tmax) of BL-M05D1 will be investigated.	Up to approximately 24 months
Secondary	T1/2	Half-life (T1/2) of BL-M05D1 will be investigated.	Up to approximately 24 months
Secondary	AUC0-t	AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.	Up to approximately 24 months
Secondary	CL (Clearance)	CL in the serum of BL-M05D1 per unit of time will be investigated.	Up to approximately 24 months
Secondary	Ctrough	Ctrough is defined as the lowest serum concentration of BL-M05D1 prior to the next dose will be administered.	Up to approximately 24 months
Secondary	ADA (anti-drug antibody)	Frequency of anti-BL-M05D1 antibody (ADA) will be investigated.	Up to approximately 24 months
Secondary	Phase Ib: Objective Response Rate (ORR)	ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.	Up to approximately 24 months
Secondary	Phase Ib: Disease Control Rate (DCR)	The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD]).	Up to approximately 24 months
Secondary	Phase Ib: Duration of Response (DOR)	The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.	Up to approximately 24 months